title: [Prophylaxis of vitamin D deficiency in hypothyroidism in the newborn infant]. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Does vitamin D administered to children with asthma treated with inhaled glucocorticoids affect short-term growth or bone turnover? Effect of Vitamin D Supplementation on Moderate to Severe Bronchial Asthma [Plasma 25-hydroxycholecalciferol after daily vitamin D administration in comparison with massive single-dose prophylaxis (author's transl)]. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Vitamin D levels, lung function, and steroid response in adult asthma.
abstract: This study deals with the relationship between the occurrence of hypercalcemia and the administration of prophylactic doses of vitamin D in children with hypothyroidism , before and during L-thyroxine ( LT4 ) treatment .  The goal of the study was to determine the dosage of vitamin D necessary to prevent rickets without inducing hypercalcemia . There was a 23 % prevalence of hypercalcemia at the time of the diagnosis of hypothyroidism by screening whereas it was 21 % in the children who were not given vitamin D  during the first 3 months of LT4 treatment . This figure was significantly higher in those who were given vitamin D during the first 3 months of treatment and reached 70 % . However , one of the 19 children not given vitamin D presented with biological signs evoking vitamin D deficiency . In conclusion , in hypothyroid infants , vitamin D should be administered carefully during the first 6 months of treatment and restricted to children at risk for developing vitamin D deficiency BACKGROUND To our knowledge , no rigorously design ed clinical trials have evaluated the relation between vitamin D and physician-diagnosed seasonal influenza . OBJECTIVE We investigated the effect of vitamin D supplements on the incidence of  seasonal influenza A in schoolchildren . DESIGN From December 2008 through March 2009 , we conducted a r and omized , double-blind , placebo-controlled trial comparing vitamin D(3 ) supplements ( 1200 IU/d ) with placebo  in schoolchildren . The primary outcome was the incidence of influenza A , diagnosed with influenza antigen testing with a nasopharyngeal swab specimen . RESULTS Influenza A occurred in 18 of 167 ( 10.8 % ) children in the vitamin D(3 ) group compared with 31 of 167 ( 18.6 % ) children in the  placebo  group [ relative risk ( RR ) , 0.58 ; 95 % CI : 0.34 , 0.99 ; P = 0.04 ] . The reduction in influenza A was more prominent in children who had not been taking other vitamin D supplements ( RR : 0.36 ; 95 % CI : 0.17 , 0.79 ; P = 0.006 ) and who started nursery school after age 3 y ( RR : 0.36 ; 95 % CI : 0.17 , 0.78 ; P = 0.005 ) . In children with a previous diagnosis of asthma , asthma attacks as a secondary outcome occurred in 2 children receiving vitamin D(3 ) compared with 12 children receiving placebo ( RR : 0.17 ; 95 % CI : 0.04 , 0.73 ; P = 0.006 ) . CONCLUSION This study suggests that vitamin D(3 ) supplementation during the winter may reduce the incidence of influenza A , especially in specific subgroups of schoolchildren . This trial was registered at https://center.umin.ac.jp as UMIN000001373 Our objective was to assess whether administration of 25-OH-vitamin D to children with asthma treated with inhaled dry-powder budesonide 400 microg daily affects short-term growth or markers of bone turnover . We utilized a r and omized , double-blind , two-period crossover trial with run-in and washout periods of 2 weeks and treatment periods of 4 weeks duration . The setting was an Outpatient clinic in a secondary referral center . Subjects included 14 boys and 3 girls with a mean age of 11.7 ( range , 6.1 - 14.4 ) years . Interventions included 15 microg ( 600 IU ) 25-OH-vitamin D ( cholecalciferol ) in one tablet ABCDin(R ) once daily in the morning . Primary outcome measures were : lower leg growth rate , serum osteocalcin , and serum markers of type I collagen turnover , i.e. , the amino terminal propeptide of type I procollagen ( PINP ) , the carboxy terminal propeptide of type I procollagen ( PICP ) ( formation markers ) , and the carboxy terminal pyridinoline cross-linked telopeptide of type I collagen ( ICTP ) ( degradation markers ) . Secondary outcome measures were parameters of asthma control and serum 25-OH-vitamin D. Lower leg growth rate was 0.22 mm/week during vitamin D and 0.25 mm/week during placebo treatment ( NS ) . Osteocalcin was 59.9 and 57.8 microg/l during vitamin D and placebo treatment , respectively , PINP 574 and 565 microg/l , PICP 381 and 382 microg/l , and ICTP 11.5 and 11.1 microg/l , respectively ( NS ) . Serum 25-OH-vitamin D was 76.3 nmol/l and 48.2 nmol/l , respectively ( P < 0.001 ) . There were no statistically significant differences in measures of pulmonary function . In conclusion , administration of 25-OH-vitamin D does not affect short-term growth or markers of bone turnover in children with asthma treated with inhaled dry-powder budesonide 400 microg daily Objective To define the therapeutic role of vitamin D in children with moderate to severe bronchial asthma as an adjunct to st and ard treatment . Methods Hundred asthmatic children of either sex , attending the respiratory and asthma clinic were enroled in the study . Diagnosis was made on the basis of history and clinical examination . R and omization was done using sealed opaque envelop method . In addition to the treatment as per GINA guidelines , one group received oral vitamin D3 ( Cholecalciferol ) 60,000 IU per month for 6 mo and the other group received placebo powder in the form of glucose sachet with a double blinded design . Monthly follow up of every patient was done and during every visit change in severity , level of control , Peak expiratory flow rate ( PEFR ) , steroid dosage , number of exacerbations and number of emergency visits were assessed . Results Monthly doses of 60,000 IU vitamin D significantly reduced the number of exacerbations as compared to placebo ( p = 0.011 ) . PEFR significantly increased in the treatment group ( p = 0.000 ) . Monthly doses of vitamin D significantly reduced the requirement of steroids ( p = 0.013 ) and emergency visits ( p = 0.015 ) . Control of asthma was achieved earlier in patients who received monthly vitamin D. Vitamin D significantly reduced the level of severity of asthma patients over 6 mo of treatment ( p = 0.016 ) . Conclusions Vitamin D has a definite role in the management of moderate to severe persistent bronchial asthma as an adjunct to st and ard treatment The effect of daily administration of 1200 IU vitamin D3 was compared with the response to a single oral dose of 200,000 IU in 21 young infants by determination of the plasma 25-OHCC levels . After about one week the mean value recorded in group 1 was 27 + /- 13 ng/ml ; the corresponding value in group 2 was 127 + /- 78.4 ng/ml . At the second control examination about one month subsequently , the mean values were 61 + /- 26.2 ng/ml and 104 + /- 69.0 ng/ml respectively . The wide range of values found in the single-dose group clearly demonstrates the advantage of daily vitamin D administration for routine prophylaxis against rickets in infancy OBJECTIVES A fixed combination of long-acting beta(2)-agonists ( LABA ) plus inhaled corticosteroids ( ICS ) has never been proven to reduce asthma exacerbations vs ICS alone in children . This 12-month , double-blind , r and omized study in 341 children ( age range , 4 to 11 years ) with asthma uncontrolled on ICS investigated whether a novel regimen using budesonide/formoterol for maintenance and reliever therapy ( Symbicort maintenance and relief therapy [ SMART ] ) [ Symbicort ; AstraZeneca R&D , Lund , Sweden ] could reduce exacerbations . METHODS Patients received SMART ( budesonide/formoterol 80/4.5 microg qd maintenance plus additional inhalations for symptom relief ) , budesonide/formoterol 80/4.5 microg qd for maintenance ( fixed combination ) , or higher-dose budesonide 320 microg qd ( fixed-dose budesonide ) . Blinded as-needed medication ( terbutaline 0.4 microg ) was provided in both fixed-dose groups . RESULTS SMART prolonged the time to first exacerbation vs fixed-dose budesonide ( p = 0.02 ) and fixed-dose combination ( p < 0.001 ) . Rates of exacerbation requiring medical intervention were reduced by 70 to 79 % with SMART vs fixed-dose budesonide and fixed-dose combination ( 0.08/patient vs 0.28/patient and 0.40/patient , respectively ; both p < 0.001 ) . Mild exacerbation days and awakenings were significantly lower with SMART ; yearly growth improved by 1.0 cm vs fixed-dose budesonide ( p < 0.01 ) . CONCLUSION The SMART regimen using budesonide/formoterol for both maintenance and as-needed symptom relief reduces the exacerbation rate compared with both fixed-dose combination and higher fixed-dose ICS alone in children with asthma RATIONALE Patients with asthma exhibit variable response to inhaled corticosteroids ( ICS ) . Vitamin D is hypothesized to exert effects on phenotype and glucocorticoid ( GC ) response in asthma . OBJECTIVES To determine the effect of vitamin D levels on phenotype and GC response in asthma . METHODS Nonsmoking adults with asthma were enrolled in a study assessing the relationship between serum 25(OH)D ( vitamin D ) concentrations  and lung function , airway hyperresponsiveness ( AHR ) , and GC response , as measured by dexamethasone-induced expression of mitogen-activated protein kinase phosphatase (MKP)-1 by peripheral blood mononuclear cells . MEASUREMENTS AND MAIN RESULTS A total of 54 adults with asthma ( FEV(1 ) , 82.9 + /- 15.7 % predicted [ mean + /- SD ] , serum  vitamin D  levels of 28.1 + /- 10.2 ng/ml ) were enrolled . Higher vitamin D levels were associated with greater lung function , with a 22.7 ( + /-9.3 ) ml ( mean + /- SE ) increase in FEV(1 ) for each nanogram per milliliter increase in vitamin D ( P = 0.02 ) . Participants with vitamin D insufficiency ( < 30 ng/ml ) demonstrated increased AHR , with a provocative concentration of methacholine inducing a 20 % fall in FEV(1 ) of 1.03 ( + /-0.2 ) mg/ml versus 1.92 ( + /-0.2 ) mg/ml in those with vitamin D of 30 ng/ml or higher ( P = 0.01 ) . In ICS-untreated participants , dexamethasone-induced MKP-1 expression increased with higher vitamin D levels , with a 0.05 (+/-0.02)-fold increase ( P = 0.02 ) in MKP-1 expression observed for each nanogram per milliliter increase in vitamin D , a finding that occurred in the absence of a significant increase in IL-10 expression . CONCLUSIONS In asthma , reduced vitamin D levels are associated with impaired lung function , increased AHR , and reduced GC response , suggesting that supplementation of vitamin D levels in patients with asthma may improve multiple parameters of asthma severity and treatment response . Clinical trials registered with www . clinical trials.gov ( NCT00495157 , NCT00565266 , and NCT00557180 )
target: Available evidence from this systematic review suggests that high dose vitamin D may prevent  asthma exacerbation .
background: CONTEXT Observational studies have suggested a relationship between vitamin D status and asthma-related respiratory outcomes .
  The benefit of vitamin D supplementation for pulmonary function , symptoms and exacerbations is not well established .
  OBJECTIVE To systematic ally review paediatric clinical trials investigating the role of vitamin D on asthma-related respiratory outcomes .